Ib. Squire et al., Bradykinin B-2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men, HYPERTENSIO, 36(1), 2000, pp. 132-136
Citations number
38
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
The physiological effects of angiotensin-converting enzyme (ACE) inhibition
may be in part mediated by bradykinin. We investigated the effect of coadm
inistration of the specific bradykinin B-2 receptor antagonist icatibant on
hemodynamic and neurohormonal responses to acute intravenous ACE inhibitio
n in normal men on a normal sodium diet. We performed a 4-phase, double-bli
nd, double-dummy, placebo-controlled study in 12 male volunteers. The brady
kinin antagonist icatibant (10 mg IV) was coadministered over the first 15
minutes of a 2-hour infusion of the ACE inhibitor perindoprilat (1.5 mg IV)
. Perindoprilat inhibited ACE activity and elicited the expected changes in
active renin concentration and angiotensin peptides. Over the 3 hours afte
r the start of drug infusion, perindoprilat lowered and icatibant increased
mean arterial blood pressure (each P<0.0005 versus placebo). Coadministrat
ion of icatibant attenuated the mean arterial blood pressure response to pe
rindoprilat (P<0.0005) but had no effect on neurohormonal responses to peri
ndoprilat. Our study indicates that the bradykinin B-2 receptor antagonist
icatibant attenuates the short-term blood pressure-lowering effect of acute
ACE inhibition in normal men on a normal sodium diet. Bradykinin B-2 recep
tor antagonism alone increases resting blood pressure. Bradykinin may be in
volved in the control of blood pressure in the resting state in humans.